Omnicell, Inc OMCL
We take great care to ensure that the data presented and summarized in this overview for OMNICELL, Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OMCL
View all-
Black Rock Inc. New York, NY8.18MShares$272 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.64MShares$188 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.17MShares$72.1 Million0.02% of portfolio
-
State Street Corp Boston, MA2.09MShares$69.6 Million0.0% of portfolio
-
Lazard Asset Management LLC New York, NY1.71MShares$56.9 Million0.08% of portfolio
-
Cadian Capital Management, LP New York, NY1.66MShares$55.3 Million2.77% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.1.42MShares$47.4 Million0.03% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.42MShares$47.3 Million0.03% of portfolio
-
Victory Capital Management Inc1.37MShares$45.6 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C31.36MShares$45.3 Million0.05% of portfolio
Latest Institutional Activity in OMCL
Top Purchases
Top Sells
About OMCL
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Insider Transactions at OMCL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 15
2025
|
Randall A Lipps CHAIRMAN, PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,438
-2.09%
|
$261,578
$31.69 P/Share
|
Aug 15
2025
|
Nchacha Etta EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,532
-2.74%
|
$109,492
$31.69 P/Share
|
Aug 15
2025
|
Brian H. Nutt VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,663
+30.37%
|
-
|
Aug 15
2025
|
Brian H. Nutt VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-6.43%
|
$21,111
$31.69 P/Share
|
Aug 15
2025
|
Corey J Manley EVP&CHIEF LEGAL/ADMIN OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,792
-2.38%
|
$86,552
$31.69 P/Share
|
Jun 15
2025
|
Corey J Manley EVP&CHIEF LEGAL/ADMIN OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
332
-0.28%
|
$9,628
$29.25 P/Share
|
Jun 15
2025
|
Randall A Lipps CHAIRMAN, PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,146
-0.28%
|
$33,234
$29.25 P/Share
|
Jun 01
2025
|
Bruce E Scott |
BUY
Grant, award, or other acquisition
|
Direct |
6,862
+23.0%
|
-
|
Jun 01
2025
|
Eileen J. Voynick |
BUY
Grant, award, or other acquisition
|
Direct |
6,742
+30.69%
|
-
|
Jun 01
2025
|
Edward Peter Bousa |
BUY
Grant, award, or other acquisition
|
Direct |
6,486
+26.5%
|
-
|
Jun 01
2025
|
Kaushik Ghoshal |
BUY
Grant, award, or other acquisition
|
Direct |
6,401
+30.6%
|
-
|
Jun 01
2025
|
Mark W Parrish |
BUY
Grant, award, or other acquisition
|
Direct |
6,828
+9.47%
|
-
|
Jun 01
2025
|
Robin Gene Seim |
BUY
Grant, award, or other acquisition
|
Direct |
6,828
+12.6%
|
-
|
Jun 01
2025
|
Mary Garrett |
BUY
Grant, award, or other acquisition
|
Direct |
7,084
+29.2%
|
-
|
Jun 01
2025
|
Joanne B Bauer |
BUY
Grant, award, or other acquisition
|
Direct |
7,084
+13.63%
|
-
|
May 15
2025
|
Corey J Manley EVP&CHIEF LEGAL/ADMIN OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,823
-2.35%
|
$79,044
$28.08 P/Share
|
May 15
2025
|
Nchacha Etta EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,526
-2.67%
|
$98,728
$28.08 P/Share
|
May 15
2025
|
Brian H. Nutt VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
298
-2.91%
|
$8,344
$28.08 P/Share
|
May 15
2025
|
Randall A Lipps CHAIRMAN, PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,435
-2.04%
|
$236,180
$28.08 P/Share
|
Mar 15
2025
|
Corey J Manley EVP&CHIEF LEGAL/ADMIN OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
71
-0.06%
|
$2,343
$33.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 567K shares |
---|---|
Open market or private purchase | 10.6K shares |
Payment of exercise price or tax liability | 80.5K shares |
---|---|
Open market or private sale | 12K shares |